Printer Friendly

OmniCorder Technologies Announces Corporate Name Change to Advanced BioPhotonics Inc.; New Name Better Reflects Company's Medical Imaging Technology and Transformation to Commercial Organization.

BOHEMIA, N.Y. -- OmniCorder Technologies, Inc. (OTCBB Symbol: OMCT) announced today that the company's shareholders approved a proposal to change the corporation's name to Advanced BioPhotonics Inc. at the Annual Meeting of Shareholders held yesterday. Effective immediately, the company's Over the Counter Bulletin Board ticker symbol will change to "ABPH.OB."

"Biophotonics is the science of utilizing photonic activity within tissue to detect, diagnose and treat diseases in a way that is non-invasive to the body. We were early pioneers in this field and our new name; Advanced BioPhotonics Inc. better defines the nature of our core medical imaging technology. We believe that it will further enhance our visibility within the medical and biomedical imaging marketplace, stated Denis A. O'Connor, President and Chief Executive Officer. "This name change also symbolizes the transformation the company is undergoing as we progress from a research and development stage company to a commercial organization."

The company has filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware. Holders of stock certificates bearing the name "OmniCorder Technologies, Inc." may continue to hold them and will not be required to exchange them for new certificates or take any other action.

About The Company:

Advanced BioPhotonics Inc., headquartered in Bohemia, New York, is a leading developer of functional medical imaging applications using advanced infrared focal plane arrays. Advanced BioPhotonics provides imaging technology for clinicians and researchers for drug discovery, disease detection and disease management applications.

Advanced BioPhotonics' mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting high-resolution infrared technology for biomedical applications.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 8, 2005
Previous Article:Pele Mountain Announces Option of Ardeen Project to Maple Minerals Corp and East West Resource Corporation.
Next Article:A Chinese Giant: ABI Research Spotlights ZTE.

Related Articles
Good guys, bad guys, hard cash, and the environment.
The corporation as brand: an identity dilemma.
Race Experts: How Racial Etiquette, Sensitivity Training, and New Age Therapy Hijacked the Civil Rights Revolution. (Book Reviews).
OmniCorder Completes $7.8 Million Funding; Funding Coincides With A Reverse Acquisition and Public Trading of Shares.
OmniCorder Technologies Installs BioScanIR System at Leading Italian Neurosurgical Center.
OmniCorder Technologies Announces Official Name Change and New Trading Symbol; Name and Symbol Better Reflect Company's Innovative Medical Technology...
OmniCorder Signs Agreement with Mark A. Fauci; Board of Directors Extends Voluntary Stock Lock-Up Through Year End 2005.
OmniCorder Technologies to Present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference; Presentation to Be Webcast.
Advanced BioPhotonics Inc. and the Research Foundation of State University of New York Enter into Medical Imaging Research Agreement; Company to...
A healthy change: consumer-driven health plans' success depends on empowering participants and making them accountable for their actions.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters